Pharma Pioneer

Tectonic Launches TX45 Phase 1B Trial for Group 2 PH in HFpEF Patients

19 May 2024
2 min read

Tectonic Therapeutic, a biotech firm, has commenced a Phase 1B clinical trial for TX45, a novel long-acting relaxin-Fc fusion protein, to assess its impact on the cardiovascular system of patients with Group 2 Pulmonary Hypertension (PH), a condition for which no approved treatments currently exist. The company, co-founded by Harvard Medical School professors, is hopeful that TX45's vasodilatory and anti-inflammatory characteristics can lead to better treatment outcomes for these patients. The Phase 1B study will focus on the safety and hemodynamic effects of a single dose of TX45 in patients with PH stemming from heart failure with preserved ejection fraction (HFpEF). This condition affects over 600,000 individuals in the US and is linked to high morbidity and mortality rates. The initial Phase 1A study's promising results suggest that TX45 could be a leading therapy, with further data expected in mid-2024 and Phase 1B results anticipated in 2025. Tectonic Therapeutic is utilizing its proprietary GEODe™ platform to develop innovative treatments for under-served patient populations and is planning a Phase 2 study for the second half of 2024. The company, which is based in Watertown, Massachusetts, is also in the process of merging with AVROBIO, Inc.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Viking Reports Positive Phase 1 Trial Results for VK2735 Dual Receptor Agonist
Pharma Pioneer
2 min read
Viking Reports Positive Phase 1 Trial Results for VK2735 Dual Receptor Agonist
19 May 2024
Viking Therapeutics has reported significant weight loss outcomes from a Phase 1 clinical trial of VK2735, a new dual GLP-1/GIP receptor agonist.
Read →
CinFina Pharma: FDA Approves CIN-110 IND for Obesity Treatment, Initiating Phase 1 Study with First Doses Administered
Pharma Pioneer
2 min read
CinFina Pharma: FDA Approves CIN-110 IND for Obesity Treatment, Initiating Phase 1 Study with First Doses Administered
19 May 2024
CIN-110 is being developed by CinFina Pharma, a company within the CinRx portfolio that focuses on treatments for obesity and metabolic disorders.
Read →
MEI Pharma Updates on Voruciclib and Venetoclax Combo in Relapsed/Refractory AML Clinical Trial
Pharma Pioneer
3 min read
MEI Pharma Updates on Voruciclib and Venetoclax Combo in Relapsed/Refractory AML Clinical Trial
19 May 2024
The study is assessing the combination of voruciclib, a CDK9 inhibitor, and venetoclax, a BCL2 inhibitor, for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).
Read →
TiumBio Files for Phase 1b Trial of Prolonged-Action rFVIIa TU7710 in Hemophilia Patients
Pharma Pioneer
3 min read
TiumBio Files for Phase 1b Trial of Prolonged-Action rFVIIa TU7710 in Hemophilia Patients
19 May 2024
This submission is for a Phase 1b clinical trial of TU7710, a novel recombinant activated factor VII (rFVIIa), intended to treat hemophilia A or B patients with inhibitors.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.